CNS Co.,Ltd
Notice Regarding the Appointment of Director Candidates
Appointment of new and reappointed director candidates confirmed. President Masahide Sekine will remain as Representative Director and President, with others to be appointed as Corporate Headquarters Chief, Technology Business Headquarters Chief, and outside director candidate. The selection of director candidates will be formally resolved after approval at the ordinary general meeting of shareholders on August 27, 2026. Audit & Supervisory Committee candidates will be reaffirmed similarly, with outside director candidates to be presented. The retiring person is Mr. Toyama.
Key Figures
- Representative Director and President, reappointed
- Director, Corporate Headquarters Chief, reappointed
- Director, Technology Business Headquarters Chief, reappointed
- Outside Director, reappointed (independent director candidate)
- Audit & Supervisory Committee candidate, reappointed / outside director candidate
AI要約
Appointment of director candidates
At today's board meeting, it was decided to appoint as director candidates Representative Director and President Masahide Sekine, Corporate Headquarters Chief Masatoshi Inoko, Technology Business Headquarters Chief Norihiro Onishi, and outside director candidate Reiko Iwato, among others. Note that outside director candidates have already been filed as independent directors. The formal resolutions on appointment of candidates are expected to be made at the 41st ordinary general meeting of shareholders on August 27, 2026 and at the subsequent board meeting. Audit & Supervisory Committee candidates are being determined similarly, and the retiring party is Mr. Toyama.
Important notes and future procedures
Each candidate has no special conflicts of interest, and outside director candidates have been filed as independent directors. We have executed liability for damages contracts and director/officer liability insurance contracts, and plan to renew with the same terms upon next renewal. If approved, the insured status will continue under the insurance policy.
CNS
Company overview · Stock price · Financial data · All IR